On June 9, 2026, Nasus Pharma Ltd. announced positive results from a preclinical pharmacokinetic and safety study of its intranasal Ondansetron (NS003). The company also released an updated corporate presentation on its website. Nasus Pharma is a pharmaceutical company that develops intranasal drug delivery technologies.
